Condition: Early-stage Breast Cancer · Hormone Receptor Positive Breast Carcinoma · Invasive Breast Cancer · Sponsor: Jonsson Comprehensive Cancer Center
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer. Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 expressed at low levels on cancer cells in a targeted way and delivers deruxtecan to kill them. Anastrozole works by decreasing estrogen production and suppressing the growth of tumors that need estrogen to grow. This study is evaluating how effective trastuzumab deruxtecan is at treating hormone receptor positive cancer cells that have low levels of HER2 expressed on them when given alone or in combination with anastrozole.
This description comes directly from the study's public registry record.
TRIO-US · 310-829-5471 · ISTTeam@mednet.ucla.edu
Always discuss trial participation with your own doctor first.
| St. Joseph Heritage Healthcare | Fullerton, California, United States | Recruiting |
| Cancer Blood and Specialty Clinic | Los Alamitos, California, United States | Recruiting |
| UCLA / Jonsson Comprehensive Cancer Center | Los Angeles, California, United States | Recruiting |
| Torrance Memorial Physician Network / Cancer Care | Torrance, California, United States | Recruiting |
| PIH Health | Whittier, California, United States | Recruiting |
| Orlando Health, Inc. d/b/a Orlando Health UF Health Center | Orlando, Florida, United States | Withdrawn |
| Ft. Wayne Medical Oncology and Hematology, Inc. | Fort Wayne, Indiana, United States | Withdrawn |
| Cancer Center of Kansas | Wichita, Kansas, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04553770